Once-Weekly HIV Tablet Clears Two Phase 3 Tests

Company Gilead Sciences / Merck Event Type Clinical Trial Results (Phase 3) Modality Oral Two-Drug Regimen (Capsid Inhibitor + NRTTI) Asset Lenacapavir + Islatravir Target HIV-1 Capsid / Reverse Transcriptase Disease Area HIV-1 Infection (Virologically Suppressed Switch Population) Summary Gilead and Merck disclosed detailed Week…